|
Pharmexcil to hold Chintan Shivir on long-term strategic roadmap for pharma industry on Feb 21 in Ahmedabad
|
|
Shardul Nautiyal, Mumbai
February 11 , 2026
|
|
|
In order to discuss long-term strategic roadmap for the Indian pharmaceutical industry, key stakeholders will engage in structured discussions on emerging challenges, policy priorities, regulatory frameworks, innovation, quality and exports among other areas at a Chintan Shivir 2026 on February 21, 2026 in Ahmedabad, Gujarat.
The Chintan Shivir is envisaged as a high-level deliberative platform bringing together policymakers, regulators, industry leaders, experts, other stakeholders to discuss relevant issues and solutions in the industry and come out with recommendations.
"The Pharmaceuticals Export Promotion Council of India (Pharmexcil) proposes to organize a Chintan Shivir on the pharmaceutical industry. Delegates are requested to kindly register at this stage through a registration form, to facilitate planning and coordination. Member companies have been requested to kindly submit the registration form at the earliest to confirm your participation," informs K Raja Bhanu, director general (DG), Pharmexcil.
Deliberations during the Chintan Shivir in 2025 focused on sensitising exporters, especially MSMEs, to India’s evolving international trade and cooperation framework. It also discussed on strengthening industry awareness of policy, regulatory and capacity-building initiatives relevant to pharmaceutical exports. Discussions centred on the identification of non-tariff barriers and regulatory challenges, expansion of regulatory cooperation and mutual recognition mechanisms to enable faster and more predictable approvals. It was also discussed to build a robust life sciences innovation ecosystem encompassing research and development, clinical trials, biologics, vaccines and biosimilars.
Deliberations took place on recent developments in India’s international trade framework, including the India–UK Comprehensive Economic and Trade Agreement (CETA) signed on 24 July 2025, and the India–European Free Trade Association (EFTA) Trade and Economic Partnership Agreement (TEPA), which became effective on 1 October 2025. Emphasis was placed on the binding zero-tariff provisions in these agreements and their potential to enhance the competitiveness of Indian generic medicines, as well as the investment and employment opportunities arising from them. The programme also highlighted forthcoming India–Switzerland collaboration initiatives in biotechnology and pharmaceutical innovation, including the scope for linking Swiss biotech clusters with Indian innovation hubs.
Technical sessions were held on Antimicrobial Resistance (AMR), skilled manpower development, emerging developments in the Foreign Trade Policy, the evolving GST regime and the implementation of revised Good Manufacturing Practices (GMP). Experts from the Council of Scientific and Industrial Research (CSIR)–Institute of Microbial Technology, the National Institute of Pharmaceutical Education and Research (NIPER) Mohali, the Directorate General of Foreign Trade (DGFT), the Central Drugs Standard Control Organisation (CDSCO), State Drug Control Authorities, the Life Sciences Sector Skill Development Council (LSSSDC) and industry shared insights on regulatory readiness, quality management systems (QMS), workforce competency and digital compliance mechanisms.
Pharmexcil also presented its export promotion initiatives, including its flagship event iPHEX, the 12th International Exhibition on Pharma and Healthcare Industry, scheduled to take place between September 7 and September 9, 2026, at Bharat Mandapam in New Delhi.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|